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Abstract 21 
Data on analytical sensitivity of rapid diagnostic assays are important for clinical management of influenza, 22 
especially during a pandemic. Four rapid antigen detection assays were compared for detection of pandemic 23 
influenza A H1N1 2009, seasonal H1N1 and H3N2 in 96 patients with influenza A infection confirmed by 24 
real-time RT-PCR. These rapid antigen tests appeared to have lower sensitivity (55.8%) for the diagnosis of 25 
pandemic influenza A H1N1 2009 as compared with seasonal H3N2 (71.0%) or H1N1 (69.4%) influenza 26 
infections, a difference that was related to a lower viral load in patients infected with the pandemic influenza 27 
A H1N1 2009 virus. The detection limit of these antigen detection tests in clinical specimens was an 28 
influenza A M gene copy number of average 1.0 x 10
7
 copies /ml. Significant variations between tests in 29 
sensitivity for detection of pandemic influenza A H1N1 2009 (43.4-63.3%) were observed. The Directigen 30 
EZ Influenza A+B and the Espline Influenza A+B had comparable sensitivity (63%) and were the most 31 
sensitive among the four assays evaluated.  32 
33 
1.  Introduction 34 
Influenza A virus infection is a common cause of respiratory illness and contributes to morbidity and 35 
mortality annually, particularly in young children and in the elderly. Occasionally, animal influenza viruses 36 
transmit zoonotically to humans giving rise to severe clinical diseases such as avian H5N1 (de Jong et al., 37 
2006). A novel influenza A (H1N1) 2009 (pH1N1 2009) virus of swine in origin was detected in Mexico and 38 
USA in April 2009 [Novel swine-origin influenza A (H1N1) virus investigation team, 2009]. The virus was 39 
efficient at transmitting from human to human and spread globally to cause a pandemic (Fraser et al., 2009). 40 
Rapid, simple and reliable diagnostic tests for confirming infection with influenza A can improve clinical 41 
management by guiding the appropriate use of antivirals and antibiotics. It has been previously demonstrated 42 
that the analytical sensitivity of many of these influenza A antigen detection tests for detection of avian 43 
H5N1 and pH1N1 2009 was comparable with that of seasonal influenza A infected cell lysates (Chan et al., 44 
2007 and 2009). Recently, several studies reported that these rapid kits had clinical diagnostic sensitivity 45 
ranging from 10-80% for detection of pH1N1 2009 (Cowling et al., 2010; Ginocchio et al., 2009; Gordon et 46 
al., 2010; Kumar et al., 2010, Yang et al., 2011). However, the reasons for this variable and poor sensitivity 47 
of rapid antigen assays for clinical samples with pH1N1 2009 have not been investigated. The present study 48 
is to correlate clinical diagnostic sensitivity of four commercially available rapid antigen detection tests to 49 
viral load in the clinical specimens as determined by quantitative PCR methods in patients infected with 50 
seasonal H1N1 (sH1N1), seasonal H3N2 (sH3N2) and pH1N1 2009 influenza A. The performance of these 51 
rapid kits was also compared with direct immunofluorescence antigen detection kit and conventional virus 52 
culture. 53 
2. Materials and Methods 54 
 55 
2.1  Clinical samples 56 
Ninety seven nasopharyngeal aspirate specimens collected from hospitalized patients with suspected 57 
influenza from July 2009 to January 2010 sent to the virology laboratory at the Queen Mary Hospital, Hong 58 
Kong for routine diagnosis were used for this study. These specimens were routinely tested by direct 59 
immunofluorescence antigen test, RT-PCR for influenza A and culture for virus isolation as part of routine 60 
clinical care. The rapid antigen tests evaluated here (see below) were carried out on the residual specimen 61 
left over after routine tests were completed. Fifty-six of the patients were males and 41 were females with an 62 
age range of 9 months to 104 years. This study has been approved by the Institutional Review Board of the 63 
University of Hong Kong/ Hospital Authority Hong Kong West Cluster. 64 
 65 
2.2  RT-PCR for H and M gene of influenza A 66 
The diagnosis of pH1N1 2009 virus, sH1N1 and sH3N2 was performed by real-time reverse 67 
transcriptase-polymerase chain reaction (RT-PCR) using primers targeting the hemagglutinin gene of 68 
pandemic H1N1 virus according to method described earlier (To et al., 2010, CDC 2007). The quantitation 69 
of influenza A virus was performed by using real-time quantitative RT-PCR targeting influenza A virus M 70 
gene, as described previously (Li et al., 2010). Briefly, 12 µl of eluted RNA of Influenza A virus was used 71 
for cDNA using the Invitrogen Superscript II Kit with a random primer as described, and then, cDNA was 72 
amplified in a Lightcycler instrument with a FastStart DNA Master SYBR Green I Mix reagent kit (Roche 73 
Diagnostics GmbH, Mannheim, Germany). In a typical reaction, 2 µl of cDNA was amplified in a 20 µl of 74 
LC-PCR master mix containing 1X Fast-Start DNA master SYBR green I mix, 4.0 mM MgCl2, 0.5 mM of 75 
each primer. To determine the specificity of the assay, all the PCR products were subjected to a melting 76 
curve analysis (65–95o C; 0.1o C per second) at the end of the assay. For quantitative assay, a reference 77 
standard was prepared using pCRII-TOPO vector (Invitrogen, San Diego, CA) containing the corresponding 78 
target viral sequences. A series of 6 log 10 dilution equivalent to 1 x 10
1
 to 1 x 10
6
 copies per reaction were 79 
prepared to generate calibration curves and run in parallel with the test samples. If the specimen result was 80 
outside the upper limit of the expected range, the extract of the sample was repeated with suitable dilution. 81 
The detection limit of this assay was 900 copies of RNA per milliliter.  82 
 83 
2.3  Rapid influenza antigen detection kits 84 
Four rapid influenza antigen detection kits: QuickVue influenza A+B (Quidel Corpopration, CA, USA); 85 
BinaxNow Influenza A+B (Binax, Maine, USA); Directigen EZ Flu A+B (Becton Dickinson and Company, 86 
MD, USA); and Epsline influenza A+B ((Fujirebio, Tokyo, Japan) were evaluated. All these tests were 87 
carried out according to the manufacturers’ instructions (Chan et al., 2009). Briefly, for the QuickVue 88 
influenza A + B test, 280 ul of sample was added to the extraction tube containing extraction powder. The 89 
extraction tube was swirled gently to dissolve its content. A test strip was placed into the extraction tube. The 90 
result was read at 10 minutes. The BinaxNow Influenza A + B test kit used 100 ul of specimen in a virus 91 
transport medium to the test device and the result was read after 15 minutes. For the Directigen EZ Flu A + 92 
B, 300 µl of sample was mixed with 4 drops of extraction reagent, 3 drops of the mixture was added to the 93 
well. The result was read after 15 minutes. The Espline influenza A + B used 40 µl of sample added directly 94 
to the well with the result being read after 10 minutes.  95 
 96 
2.4  Viral culture 97 
Madin-Darby canine kidney (MDCK) cell monolayers grown in culture tubes were inoculated with 200 µl of 98 
sample and incubated at 35
o 
C for 1 hour. The cells were fed with 1 ml of serum-free minimum essential 99 
medium containing TPCK (tosylsulfonyl phenylalanylchloromethyl ketone)-treated trypsin (2µg/ml) (Sigma, 100 
St. Louis, Mo) and antibiotics (Garamycin, 0.02 mg/ml, Schering-Plough Corporation, Heist-op-den-Berg, 101 
Belgium; Penicillin-streptomycin, 100 units/ml, GibcoBRL, NY, USA; Nystatin, 20 units/ml, Sigma, St. 102 
Louis, Mo). The cultures were harvested when cytopathic effect (CPE) was observed or after 10 days 103 
incubation period for direct immunofluorescent antigen test as described previously (Chan et al., 2008). 104 
 105 
2.5  Direct immunofluorescence antigen test  106 
The direct immunofluorescence antigen  test was carried out with nasopharyngeal aspirate specimens 107 
according to method described previously (Chan et al., 2008). Briefly, the nasopharyngeal aspirate was 108 
centrifuged, and the cell pellet was washed in phosphate-buffered saline. The cell pellet was then spotted on 109 
6-mm wells of Teflon-coated slides, air dried, and fixed in ice-cold acetone for 10 minutes. The smears were 110 
stained with IMAGEN
TM
 influenza A and B reagents (Oxoid Limited, Hampshire, UK) and then viewed at a 111 
magnification of 400 under epifluorescent illumination using the fluorescein isothiocyanate (FITC) filter of a 112 
Nikon fluorescent microscope.  113 
 114 
 115 
3. Results 116 
3.1 Laboratory tests for diagnosis of influenza A infections 117 
Ninety-seven nasopharyngeal aspirates collected were tested by RT-PCR for amplification of matrix (M) and 118 
subtype-specific hemagglutinin (H) gene assays for diagnosis of influenza A infection. Direct 119 
immunofluorescent antigen test and culture were done on all specimens for influenza A. Of these 97 120 
influenza A positives, 30, 31 and 36 were identified as pH1N1 2009, sH1N1 and sH3N2 respectively.  121 
 122 
3.2 Rapid influenza antigen detection kits performance 123 
The data presented in Table 1 shows that the Directigen EZ Influenza A+B and the Espline Influenza A+B 124 
exhibited apparently higher levels of sensitivity for detection of pH1N1 2009 (63.3%), compared with the 125 
QuickVue A+B (53.3%) and the BinaxNow (43.3%) but this difference is not statistically significant 126 
(Chi-squared test, p = 0.6). However, the four RDA tests have the similar levels of sensitivity for detection 127 
of sH1N1 (71.0%) or sH3N2 (66.7%-72.2%).  128 
 129 
 130 
3.3 Viral load of influenza A subtype in nasopharyngeal aspirate  131 
The mean of viral load of Influenza A RNA subtype sH3N2 in nasopharyngeal aspirate samples was the 132 
highest when compared with influenza A subtype sH1N1 or pH1N1 (Table 2) and these differences were 133 
statistically significant (pH1N1 vs sH3N2 p=0.033; pH1N1 vs sH1N1 p=0.047). The limit of detection for 134 
each rapid antigen test is defined as the viral load at which ≥ 95% of specimens were positive in that test. 135 
Therefore the lower limit of viral load detection for each influenza A subtype (pH1N1, sH1N1 and sH3N2 136 
by RDA was as follows: the Directigen EZ Influenza A+B (1.1 x 10
7
, 4.4 x 10
6 
and 1.1 x 10
7
); the Espline 137 
Influenza A+B (1.1 x 10
7
, 4.4 x 10
6 
and 1.1 x 10
7
); the QuickVue Influenza A+B (1.5 x 10
7
, 4.4 x 10
6
 and 138 
4.5 x 10
6
) and the BinaxNOW Influenza A+B (3.5 x 10
7
, 4.4 x 10
6
 and 4.5 x 10
6
) (Fig 1). The average lower 139 
limit for detection of each subtype by these rapid antigen assays is pH1N1 (1.8 x 10
7
), sH1N1 (4.4 x 10
6
) 140 
and sH3N2 (7.8 x 10
6
) (Table 2). 141 
 142 
3.4 Direct immunofluorescence antigen and culture performance 143 
Sensitivity for detection of influenza A subtype by direct immunofluorescence antigen test for sH1N1, 144 
pH1N1 and sH3N2 infections was 66.7%, 87.1% and 77.8% respectively (Table 2). Virus isolation from all 145 
the samples was attempted on MDCK cells in the presence of TPCK treated trypsin. The isolation rate was 146 
similar among the three influenza A subtypes (Table 2).  147 
 148 
149 
4. Discussion 150 
Previous report showed that these rapid antigen assays had comparable sensitivity to detect pH1N1 and 151 
sH1N1 using cell culture grown viruses (Chan et al., 2009). To further understand the analytical sensitivity 152 
of these rapid assays in clinical settings, the performance of rapid antigen assays on nasopharyngeal aspirate 153 
samples was assessed and compared with viral load by RT-PCR assays. The clinical diagnostic sensitivity of 154 
rapid antigen assays for detection of influenza depends on the quality, quantity, site and viral load of clinical 155 
specimens used in the assay method as well as its analytical sensitivity (Chan et al., 2007). The sensitivity of 156 
all these assays was comparable for the detection of sH1N1and sH3N2 respectively. Any marginal 157 
difference in sensitivity between tests may be related to the volume of sample recommended for use in the 158 
assay methods. It was reported that larger test volumes gave rise to more sensitive methods (Chan et al., 159 
2007). On the contrary, there was significant variation in the ability of these four assays to detect pH1N1 160 
(Table 1). The Directigen EZ Influenza A+B and the Espline Influenza A+B were the most sensitive among 161 
the assays evaluated. These findings are also observed in previous study using culture infected cells (Chan et 162 
al., 2009; Hurt et al., 2009). 163 
 164 
The influenza A M gene copy number in each clinical sample by RT-PCR have been determined. The 165 
highest RNA M gene copy number was found in patients with sH3N2 (2.5 to 5 folds higher) than for patients 166 
with sH1N1 or pH1N1 infection. The detection limits of the rapid antigen assays for determination of these 167 
subtypes are comparable (Fig. 1). The influenza A subtypes in the sample will generally not be detectable by 168 
the rapid antigen assays if the viral load is below 1.0 x 10
7
 copies per ml (Table 2). These clinical derived 169 
detection limits are comparable with the detection limits using laboratory culture isolate (Chan et al., 2009).  170 
 171 
The rapid antigen assays were shown to have better performance for the detection of human seasonal 172 
influenza A than pH1N1 A in this study. Similarly, the direct immunofluorescence antigen test also shows 173 
the highest sensitivity for detection of human seasonal influenza A than pH1N. Since their detection limits 174 
for identification of these influenza A subtypes were comparable, the difference in clinical sensitivity is 175 
likely to be related to the viral RNA load present in the sample. However, whether there are differences in 176 
the affinity of the antibodies used in these different assays that may contribute to these differences in 177 
performance cannot be excluded but such differences was not noted in the analytical sensitivity evaluation 178 
using cultured virus (Chan et al., 2009).   179 
 180 
Epidemiological and virological studies of the pH1N1 2009 have identified several risk factors for severe 181 
infection, including host predisposing factors e.g. extremes of age, chronic underlying diseases, pregnancy, 182 
obesity; viral factors and specific mutations of viral proteins such as the D222G mutation in the 183 
hemagglutinin (Chen et al., 2010; Lapinsky et al., 2010; Louie et al., 2011). There are also differences in the 184 
type of specimen used, with tracheal aspirates giving higher diagnostic yield that nasopharyngeal aspirates in 185 
patients who are more seriously ill (Lee et al 2011).  186 
 187 
Rapid point of care antigen detection tests continue to be used for clinical care, especially in out-patient 188 
settings and for diagnosing and controlling influenza outbreaks in institutions. It is therefore important to 189 
define the clinical diagnostic performance characteristics of these rapid antigen assays. The present studies 190 
indicate that the lower clinical sensitivity of rapid antigen assays for pandemic influenza A H1N1 2009 191 
infection is associated with lower viral load found in these patients.   192 
 193 
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Legend 272 
Table 1 Performance of the four rapid antigen assays for detection of different influenza A subtypes 273 
 274 
Table 2 Compare different methods for diagnosis of influenza infections 275 
 276 
Fig. 1 Viral RNA M gene copy number present in patient with pH1N1, sH1N1 and sH3N2 are denoted 277 
together with the rapid antigen test results for each test kit. The limit of detection for each rapid antigen test 278 
is denoted by a horizontal line as the viral load at which ≥ 95% of specimens were positive in that test. 279 
280 
Table 1 Performance of the four rapid antigen assays for detection of different influenza A subtypes  281 
 282 
Influenza A subtypes 
(No. of patients) 
BinaxNOW 
Influenza  
A+B 
QuickVue 
Influenza  
A+B 
Directigen EZ 
Influenza 
A+B 
Espline 
Influenza 
A+B 
pH1N1 2009 43.3% 53.3% 63.3% 
 
63.3% 
= 30     
     
sH1N1 71.0% 71.0% 71.0% 
 
71.0% 
=31        
      
sH3N2 66.7% 72.2% 69.4% 
 
69.4% 
=36        
      
 283 
284 
 Table 2  Compare different methods for diagnosis of influenza infections 285 
 286 
 287 
 288 
 289 
 290 
 291 
 292 
 293 
 294 
 295 
 296 
 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
 313 
 314 
 315 
 316 
 317 
 318 
 319 
 320 
Influenza A subtype Mean of viral load  IF Culture Rapid detection assays  
= No. of patients (copies/ml) 
(Range)     
Mean of 
(Detection limit) 
pH1N1 2009 1.83 x 10
8 
 66.7% 96.7% 55.8% 
=30         
  (6.37 x 10
2
 - 2.00 x 10
9
)     (1.8 x10
7
)  
sH1N1 3.89 x 10
8
 87.1% 97.0% 71.0% 
=31       
  (5.40 x 10
4
 - 3.40 x 10
10
)     (4.4 x10
6
) 
sH3N2 9.63 x 10
8
 77.8% 97.2% 69.4% 
=36       
  (2.34 x 10
4 
- 1.17 x 10
10
)     (7.8 x10
6
) 
Overall  5.12E+08 77.2% 97.0% 65.4%  
Mean 
 
    
(1.0 x 10
7
)   
Fig. 1 Viral RNA M gene copy number present in patient with pH1N1, sH1N1 and sH3N2 are denoted 321 
together with the rapid antigen test results for each test kit. The limit of detection for each rapid antigen test 322 
is denoted by a horizontal line as the viral load at which ≥ 95% of specimens were positive in that test. 323 
 324 
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